Session Y45: Focus Session: Physics of Cancer II

8:00 AM–11:00 AM, Friday, March 22, 2013
Hilton Baltimore Room: Holiday Ballroom 4

Sponsoring Unit: DBIO
Chair: Larry Nagahara, National Institutes of Health

Abstract ID: BAPS.2013.MAR.Y45.4

Abstract: Y45.00004 : Ultrasensitive Mirco-Hall Detector for Enumeration and Molecular Profiling of Rare Cells

8:36 AM–8:48 AM

Preview Abstract MathJax On | Off   Abstract  

Authors:

  Changwook Min
    (Massachusetts General Hospital)

  David Issadore
    (University of Pennsylvenia)

  Jaehoon Chung
    (Massachusetts General Hospital)

  Huilin Shao
    (Massachusetts General Hospital)

  Monty Liong
    (Massachusetts General Hospital)

  Arezou A. Ghazani
    (Massachusetts General Hospital)

  Cesar M. Castro
    (Massachusetts General Hospital)

  Ralph Weissleder
    (Massachusetts General Hospital)

  Hakho Lee
    (Massachusetts General Hospital)

We have recently developed a miniaturized microfluidic chip-based technology, the micro-Hall detector (uHD), that can perform rapid, highly sensitive, and quantitative measurement of individual cells in unprocessed biological samples. The uHD detects the Hall voltage induced by magnetic moments of cells in-flow that have been immunomagnetically tagged with magnetic nanoparticles (MNPs) and bio-orthogonal chemistry. The entire assay is performed on a single microfluidic chip with minimal sample preparation to avoid sample loss and to simplify assay procedure, eliminating the need for any washing and purification steps, and thereby allows cellular diagnostics to be conducted in point-of-care clinical settings. We also demonstrated simultaneous detection of heterogeneous biomarkers on individual cells by targeting different cellular markers with a panel of MNPs. The quantity of each MNP type, and hence the expression level of a target biomarker in a single cell, could be obtained using the particles' distinctive magnetization properties. The clinical use of the uHD was explored by the detection of circulating tumor cells (CTCs) in whole blood of 20 ovarian cancer patients, and drug treatment efficacy was monitored in a mouse tumor model.

To cite this abstract, use the following reference: http://meetings.aps.org/link/BAPS.2013.MAR.Y45.4